AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16638415 — intervention group
Group type: COMPARATOR
Intervention: Alefacept IM
Number of subjects: 50
Study 16638415 — intervention group
Group type: EXPERIMENTAL
Intervention: Alefacept SC and IM
Number of subjects: 50
Study 12889718 — intervention group
Group type: EXPERIMENTAL
Intervention: RA+HQ+FA (tretinoin 0.05%, hydroquinone 4.0%, fluocinolone acetonide 0.01%)
Number of subjects: 641
Study 12889718 — intervention group
Group type: COMPARATOR
Intervention: Dual-combination agents (RA+HQ, RA+FA, HQ+FA)
Number of subjects: 641
Study 11109969 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting dose of recombinant follicle stimulating hormone (FSH) followed by highly purified urinary FSH
Number of subjects: 46
Study 11109969 — intervention group
Group type: COMPARATOR
Intervention: Highly purified urinary FSH alone
Number of subjects: 46
Study 8630607 — intervention group
Group type: EXPERIMENTAL
Intervention: Home pressure support device
Number of subjects: 7
Study 8630607 — intervention group
Group type: COMPARATOR
Intervention: Intensive care pressure support device
Number of subjects: 7
Study 1426207 — intervention group
Group type: EXPERIMENTAL
Intervention: Zardaverine (6 mg total dose, 4 puffs at 15 min intervals)
Number of subjects: 12
Study 1426207 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1426207 — intervention group
Group type: EXPERIMENTAL
Intervention: Zardaverine
Number of subjects: 12
Study 31627016 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccination (PCV) post-2010
Number of subjects: 800
Study 31627016 — intervention group
Group type: COMPARATOR
Intervention: Pneumococcal polysaccharide vaccine (PPV) pre-2010
Number of subjects: 800
Study 31627016 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccination (PCV) post-2010 in auto‐HSCT
Number of subjects: 800
Study 31627016 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal conjugate vaccination (PCV) post-2010 in allo‐HSCT
Number of subjects: 800
Study 31538304 — intervention group
Group type: EXPERIMENTAL
Intervention: Diroximel fumarate (DRF)
Number of subjects: 696
Study 27823981 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive transcranial magnetic stimulation (rTMS)
Number of subjects: 30
Study 25395609 — intervention group
Group type: EXPERIMENTAL
Intervention: New amino acid-based formula (AAF)
Number of subjects: 33
Study 25395609 — intervention group
Group type: COMPARATOR
Intervention: Commercial amino acid-based formula (AAF)
Number of subjects: 33
Study 24114082 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed condition sequence
Number of subjects: 7
Study 24114082 — intervention group
Group type: COMPARATOR
Intervention: Random condition sequence
Number of subjects: 7
Study 21273036 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole (40 mg twice daily for 7 days)
Number of subjects: 665
Study 21273036 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 665
Study 21273036 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Number of subjects: 665
Study 19148687 — intervention group
Group type: EXPERIMENTAL
Intervention: Autogenous iliac crest cancellous bone
Number of subjects: 40
Study 19148687 — intervention group
Group type: COMPARATOR
Intervention: Allogenic cancellous bone graft
Number of subjects: 40
Study 17924872 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of cinnamon (OGTT(cin))
Number of subjects: 7
Study 17924872 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 g of cinnamon taken 12 h before (OGTT(cin12hpre))
Number of subjects: 7
Study 17924872 — intervention group
Group type: COMPARATOR
Intervention: 5 g placebo (OGTT(control))
Number of subjects: 7
Study 15194892 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day recall period
Number of subjects: 7674
Study 15194892 — intervention group
Group type: EXPERIMENTAL
Intervention: 4-week recall period
Number of subjects: 7674
Study 15194892 — intervention group
Group type: EXPERIMENTAL
Intervention: Version 3 interview
Number of subjects: 7674
Study 15194892 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week recall period
Number of subjects: 7674
Study 12351302 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT)
Number of subjects: 50
Study 12351302 — intervention group
Group type: COMPARATOR
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 50
Study 12351302 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Tube (LT) and Laryngeal Mask Airway (LMA)
Number of subjects: 50
Study 9537699 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium-restricted diet (500 mg/day, oxalate-rich products discouraged, normalization of animal protein and sodium)
Number of subjects: 25
Study 9537699 — intervention group
Group type: COMPARATOR
Intervention: No restrictions (Control group)
Number of subjects: 25
Study 7863142 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet group
Number of subjects: 158
Study 7863142 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical exercise group
Number of subjects: 158
Study 7863142 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and physical exercise group
Number of subjects: 158
Study 7863142 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 158
Study 2688437 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile glucagon and continuous insulin
Number of subjects: 6
Study 2688437 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsatile delivery of both insulin and glucagon
Number of subjects: 6
Study 2688437 — intervention group
Group type: EXPERIMENTAL
Intervention: Both insulin and glucagon delivered intermittently and out of phase
Number of subjects: 6
Study 2688437 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of insulin and glucagon
Number of subjects: 6
Study 4443501 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 treatment strategies
Number of subjects: 139
Study 4443501 — intervention group
Group type: COMPARATOR
Intervention: Control treatment strategy
Number of subjects: 139
Study 31601285 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium energy turnover (ET) during energy balance (EB)
Number of subjects: 9
Study 31601285 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy turnover (ET) during energy balance (EB)
Number of subjects: 9
Study 31601285 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium energy turnover (ET) during overfeeding (OF)
Number of subjects: 9
Study 31601285 — intervention group
Group type: EXPERIMENTAL
Intervention: High energy turnover (ET) during overfeeding (OF)
Number of subjects: 9
Study 31601285 — intervention group
Group type: COMPARATOR
Intervention: Low energy turnover (ET) during energy balance (EB)
Number of subjects: 9
Study 31601285 — intervention group
Group type: COMPARATOR
Intervention: Low energy turnover (ET) during overfeeding (OF)
Number of subjects: 9
Study 31601285 — intervention group
Group type: COMPARATOR
Intervention: Energetic restriction (ER)
Number of subjects: 9
Study 30422156 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab (arm A)
Number of subjects: 132
Study 30422156 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy plus cetuximab (arm B)
Number of subjects: 132
Study 29051274 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release oral morphine
Number of subjects: 20
Study 26200526 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior repositioning occlusal splints (ARS) with counseling
Number of subjects: 60
Study 26200526 — intervention group
Group type: EXPERIMENTAL
Intervention: Nociceptive Trigeminal Inhibition Clenching Suppression System devices (NTI‐tss) with counseling
Number of subjects: 60
Study 26200526 — intervention group
Group type: COMPARATOR
Intervention: Counseling for behavioral changes and self-care (Control group)
Number of subjects: 60
Study 23270921 — intervention group
Group type: EXPERIMENTAL
Intervention: Video plus verbal feedback
Number of subjects: 54
Study 23270921 — intervention group
Group type: COMPARATOR
Intervention: Verbal feedback
Number of subjects: 54
Study 23270921 — intervention group
Group type: COMPARATOR
Intervention: Experiential feedback
Number of subjects: 54
Study 21206931 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomegranate mouthrinse
Number of subjects: 30
Study 21206931 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine mouthrinse
Number of subjects: 30
Study 21206931 — intervention group
Group type: COMPARATOR
Intervention: Distilled water (placebo)
Number of subjects: 30
Study 19435520 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinically integrated e‐learning course
Number of subjects: 61
Study 19435520 — intervention group
Group type: COMPARATOR
Intervention: Traditional lecture based course
Number of subjects: 61
Study 17366451 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHP)
Number of subjects: 334
Study 17366451 — intervention group
Group type: COMPARATOR
Intervention: Artesunate-amodiaquine (AAQ)
Number of subjects: 334
Study 15541529 — intervention group
Group type: EXPERIMENTAL
Intervention: Bimanual task
Number of subjects: 78
Study 11673036 — intervention group
Group type: EXPERIMENTAL
Intervention: Subconjunctival administration of 20 mg vancomycin
Number of subjects: 100
Study 11673036 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of 1 g b.i.d. vancomycin
Number of subjects: 100
Study 9037131 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with carbimazole and TSH suppressive dose of T4 for 12 months, followed by another 12 months of TSH suppressive therapy alone
Number of subjects: 50
Study 9037131 — intervention group
Group type: COMPARATOR
Intervention: Carbimazole for one year with T4 added as needed to normalize elevated TSH, no therapy during the second year
Number of subjects: 50
Study 9037131 — intervention group
Group type: EXPERIMENTAL
Intervention: TSH suppressive treatment
Number of subjects: 50
Study 7886281 — intervention group
Group type: EXPERIMENTAL
Intervention: All‐Erroneous KR condition (received erroneous knowledge of results during acquisition)
Number of subjects: 0
Study 7886281 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed‐Correct KR condition (received 50 trials of correct KR followed by 25 trials of erroneous KR)
Number of subjects: 0
Study 7886281 — intervention group
Group type: EXPERIMENTAL
Intervention: Erroneous KR condition (received erroneous knowledge of results during acquisition)
Number of subjects: 0
Study 3061717 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (40 mg)
Number of subjects: 0
Study 3061717 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (50 mg)
Number of subjects: 0
Study 3061717 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide (40 mg) followed by standing
Number of subjects: 0
Study 3061717 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril administration in the supine position
Number of subjects: 0
Study 3061717 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril administration
Number of subjects: 0
Study 3061717 — intervention group
Group type: EXPERIMENTAL
Intervention: Frusemide injection and standing
Number of subjects: 0
Study 30620067 — intervention group
Group type: EXPERIMENTAL
Intervention: COST‐Africa BSc training programme
Number of subjects: 17
Study 30620067 — intervention group
Group type: EXPERIMENTAL
Intervention: COST‐Africa trainees
Number of subjects: 17
Study 30620067 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 17
Study 28089784 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-NST axillary node evaluation procedures (fine needle aspiration, core needle biopsy, sentinel node biopsy)
Number of subjects: 704
Study 28089784 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-NST sentinel node biopsy
Number of subjects: 704
Study 28089784 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-NST axillary lymph node dissection (ALND)
Number of subjects: 704
Study 28089784 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-NST axillary evaluation
Number of subjects: 704
Study 28089784 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-NST clinical and radiologic staging
Number of subjects: 704
Study 25809628 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate therapy and Black seed oil (80 mg/kg/day for one week after each methotrexate dose)
Number of subjects: 40
Study 25809628 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate therapy and placebo
Number of subjects: 40
Study 24010577 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg cobimetinib oral dose with high-fat meal
Number of subjects: 53
Study 24010577 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg cobimetinib oral dose (tablets)
Number of subjects: 53
Study 24010577 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg rabeprazole daily for 5 days prior to cobimetinib administration
Number of subjects: 53
Study 24010577 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg intravenous infusion of cobimetinib
Number of subjects: 53
Study 21961644 — intervention group
Group type: EXPERIMENTAL
Intervention: Single intravenous dose of Co-Amoxiclav (Enhancin) at induction
Number of subjects: 126
Study 21961644 — intervention group
Group type: COMPARATOR
Intervention: Five days oral course of Co-Amoxiclav postoperatively
Number of subjects: 126
Study 19646778 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical pimecrolimus applied twice daily for 5 weeks
Number of subjects: 24
Study 19646778 — intervention group
Group type: COMPARATOR
Intervention: Observation sides of face (no treatment)
Number of subjects: 24
Study 17576937 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept 50 mg twice weekly
Number of subjects: 618
Study 17576937 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 618
Study 16260197 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (10 mg intravenously every 12 hours until delivery and 3 additional doses after delivery for pregnant women; 3 doses of 10 mg after delivery for puerperal women)
Number of subjects: 132
Study 16260197 — intervention group
Group type: COMPARATOR
Intervention: Placebo (same schedule as dexamethasone)
Number of subjects: 132
Study 16260197 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 132
Study 11904595 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine (1% instilled onto the Fallopian tubes)
Number of subjects: 24
Study 11904595 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 24
Study 10588591 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐4R 1,500 microg
Number of subjects: 25
Study 10588591 — intervention group
Group type: EXPERIMENTAL
Intervention: IL‐4R 500 microg
Number of subjects: 25
Study 10588591 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study 7782486 — intervention group
Group type: EXPERIMENTAL
Intervention: Lormetazepam
Number of subjects: 12
Study 7782486 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolpidem
Number of subjects: 12
Study 7782486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2179550 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (5 mg/kg)
Number of subjects: 92
Study 2179550 — intervention group
Group type: COMPARATOR
Intervention: D-penicillamine (250 mg)
Number of subjects: 92
Study 7191300 — intervention group
Group type: EXPERIMENTAL
Intervention: triamterene preparation 1
Number of subjects: 6
Study 7191300 — intervention group
Group type: EXPERIMENTAL
Intervention: triamterene preparation 2
Number of subjects: 6
Study 7191300 — intervention group
Group type: EXPERIMENTAL
Intervention: triamterene preparation 3
Number of subjects: 6
Study 31963636 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral piercings
Number of subjects: 387
Study 31591263 — intervention group
Group type: EXPERIMENTAL
Intervention: Omega-3 carboxylic acids (OM3-CA)
Number of subjects: 0
Study 31591263 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 0
Study 27611807 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term maintenance program after initial pulmonary rehabilitation (PR) for 3 years
Number of subjects: 143
Study 27611807 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring program (Control Group)
Number of subjects: 143
Study 26010890 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended treatment (four face-to-face sessions and a smartphone application)
Number of subjects: 93
Study 26010890 — intervention group
Group type: COMPARATOR
Intervention: Full behavioural activation treatment (ten sessions)
Number of subjects: 93
Study 26010890 — intervention group
Group type: EXPERIMENTAL
Intervention: Blended treatment
Number of subjects: 93
Study 26010890 — intervention group
Group type: COMPARATOR
Intervention: Blended treatment vs Full treatment
Number of subjects: 93
Study 23066879 — intervention group
Group type: EXPERIMENTAL
Intervention: Nordic walking (NW)
Number of subjects: 0
Study 23066879 — intervention group
Group type: COMPARATOR
Intervention: Usual overground walking (OW)
Number of subjects: 0
Study 21602713 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg
Number of subjects: 177
Study 21602713 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 177
Study 19052779 — intervention group
Group type: EXPERIMENTAL
Intervention: Outpatient cognitive behavioural treatment (CBT)
Number of subjects: 116
Study 16449106 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley with extra-amniotic saline infusion
Number of subjects: 140
Study 16449106 — intervention group
Group type: COMPARATOR
Intervention: Foley alone
Number of subjects: 140
Study 15267006 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume expansion with 300 ml saline during CM administration
Number of subjects: 39
Study 15267006 — intervention group
Group type: COMPARATOR
Intervention: Intravenous administration of at least 2,000 ml saline within 12 h before and after CM application
Number of subjects: 39
Study 11687322 — intervention group
Group type: EXPERIMENTAL
Intervention: Course in psychosocial oncology for nurses, consisting of four 3-hour weekly lessons and follow-up discussions at termination and 5 months later.
Number of subjects: 6
Study 9224082 — intervention group
Group type: EXPERIMENTAL
Intervention: Aciclovir suspension 15 mg/kg five times a day for seven days
Number of subjects: 72
Study 9224082 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 8463201 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with autism
Number of subjects: 3
Study 8463201 — intervention group
Group type: EXPERIMENTAL
Intervention: Children with RDLD
Number of subjects: 3
Study 8463201 — intervention group
Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 3
Study 3606933 — intervention group
Group type: EXPERIMENTAL
Intervention: Food intake (standard breakfast)
Number of subjects: 24
Study 29134614 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradiaytic exercise (20 minutes)
Number of subjects: 9
Study 29134614 — intervention group
Group type: COMPARATOR
Intervention: Control hemodialysis session
Number of subjects: 9
Study 26947328 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (250 mg daily)
Number of subjects: 151
Study 26947328 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 151
Study 24749642 — intervention group
Group type: EXPERIMENTAL
Intervention: Reappraising arousal as beneficial
Number of subjects: 0
Study 24749642 — intervention group
Group type: COMPARATOR
Intervention: No instructions (control)
Number of subjects: 0
Study 23927603 — intervention group
Group type: EXPERIMENTAL
Intervention: CKD-specific computer decision support (CDS) plus practice facilitation (TRANSLATE model)
Number of subjects: 2000
Study 23927603 — intervention group
Group type: COMPARATOR
Intervention: CKD-specific computer decision support (CDS) alone
Number of subjects: 2000
Study 20589368 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly bisphosphonates
Number of subjects: 0
Study 20589368 — intervention group
Group type: COMPARATOR
Intervention: Daily bisphosphonates
Number of subjects: 0
Study 20589368 — intervention group
Group type: COMPARATOR
Intervention: Monthly bisphosphonates
Number of subjects: 0
Study 20589368 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual zoledronic acid infusions
Number of subjects: 0
Study 19430310 — intervention group
Group type: EXPERIMENTAL
Intervention: Torasemide (8 mg/d)
Number of subjects: 30
Study 19430310 — intervention group
Group type: COMPARATOR
Intervention: Azosemide (60 mg/d)
Number of subjects: 30
Study 17056786 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-based training for laparoscopic suturing and knot-tying
Number of subjects: 11
Study 17056786 — intervention group
Group type: COMPARATOR
Intervention: Senior-level surgery residents performing laparoscopic suturing and knot-tying
Number of subjects: 11
Study 12783427 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous transcranial 2 MHz Doppler ultrasound (C-US) monitoring over 1 hour
Number of subjects: 25
Study 12783427 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ultrasound)
Number of subjects: 25
Study 10961522 — intervention group
Group type: EXPERIMENTAL
Intervention: gl-30 (glucose ingestion 30 min prior)
Number of subjects: 8
Study 10961522 — intervention group
Group type: EXPERIMENTAL
Intervention: gl-60 (glucose ingestion 60 min prior)
Number of subjects: 8
Study 10961522 — intervention group
Group type: EXPERIMENTAL
Intervention: gl-90 (glucose ingestion 90 min prior)
Number of subjects: 8
Study 10961522 — intervention group
Group type: COMPARATOR
Intervention: pl-60 (placebo 60 min prior)
Number of subjects: 8
Study 9322191 — intervention group
Group type: EXPERIMENTAL
Intervention: Olive oil (40 g of fat/m2 body surface area)
Number of subjects: 8
Study 9322191 — intervention group
Group type: COMPARATOR
Intervention: Milk fat (40 g of fat/m2 body surface area)
Number of subjects: 8
Study 9322191 — intervention group
Group type: COMPARATOR
Intervention: Safflower oil (40 g of fat/m2 body surface area)
Number of subjects: 8
Study 8358459 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia
Number of subjects: 83
Study 8358459 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular injections
Number of subjects: 83
Study 3065738 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil (0.4 mg/kg orally days 5 and 6) plus prednisone (60 mg/m2 orally days 1 to 4) every 2 weeks (CL + PDN)
Number of subjects: 96
Study 3065738 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide (160 mg/m2 orally days 1 to 4), melphalan (6 mg/m2 orally days 1 to 4), and prednisone (60 mg/m2 orally days 1 to 4) every 3 weeks for 10 months (CMP)
Number of subjects: 96